- Previous Close
0.7943 - Open
0.0000 - Bid 0.7870 x --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 1.0660 - Volume
22,650 - Avg. Volume
111,181 - Market Cap (intraday)
629.042M - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date May 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
www.pharming.comRecent News: 0QCO.IL
View MorePerformance Overview: 0QCO.IL
Trailing total returns as of 3/19/2025, which may include dividends or other distributions. Benchmark is AEX-Index (^AEX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0QCO.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0QCO.IL
View MoreValuation Measures
Market Cap
539.97M
Enterprise Value
489.06M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.01
Price/Book (mrq)
2.65
Enterprise Value/Revenue
1.80
Enterprise Value/EBITDA
30.47
Financial Highlights
Profitability and Income Statement
Profit Margin
-7.96%
Return on Assets (ttm)
-4.10%
Return on Equity (ttm)
-8.21%
Revenue (ttm)
206.3M
Net Income Avi to Common (ttm)
-16.42M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
192.37M
Total Debt/Equity (mrq)
84.91%
Levered Free Cash Flow (ttm)
11.83M